Aytu BioScience Signs Exclusive Agreement for EXXUA

Aytu BioScience ( (AYTU) ) has shared an update.

On June 5, 2025, Aytu BioPharma entered an Exclusive Commercialization Agreement with Fabre-Kramer Holdings to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, an FDA-approved treatment for major depressive disorder (MDD), is expected to launch in the fourth quarter of 2025. The agreement involves a series of financial commitments, including upfront and milestone payments, royalties, and a supply price based on net sales. EXXUA is anticipated to be a significant growth catalyst for Aytu, addressing unmet needs in the $22 billion US prescription MDD market. The product is distinguished by its novel mechanism and lack of sexual dysfunction side effects, positioning it as a transformative option for over 21 million Americans affected by MDD.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Spark’s Take on AYTU Stock

According to Spark, TipRanks’ AI Analyst, AYTU is a Neutral.

The overall score reflects strong earnings call outcomes with significant revenue growth and operational improvements, but is weighed down by ongoing profitability challenges and negative cash flow. Technical analysis provides mixed signals, while valuation challenges persist due to a negative P/E ratio and lack of dividends.

To see Spark’s full report on AYTU stock, click here.

More about Aytu BioScience

Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. The company’s prescription products include EXXUA™ (gepirone) extended-release tablets for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® for attention deficit hyperactivity disorder (ADHD), and a line of legacy products.

Average Trading Volume: 1,208,108

Technical Sentiment Signal: Sell

Current Market Cap: $9.81M

For a thorough assessment of AYTU stock, go to TipRanks’ Stock Analysis page.